The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells

BMC Complementary and Alternative Medicine

Volumn 15, Issue 1, 2015, Pages

  Mayr, Christian ^a   Wagner, Andrej ^a   Neureiter, Daniel ^a   Pichler, Martin ^b   Jakab, Martin ^a   Illig, Romana ^a   Berr, Frieder ^a   Kiesslich, Tobias ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biliary tract cancer; Cell cycle arrest; Cisplatin; Drug synergism; EGCG; Green tea

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CASPASE; CD133 ANTIGEN; CISPLATIN; DEATH RECEPTOR 5; EPIGALLOCATECHIN GALLATE; MESSENGER RNA; PROTEIN P21; ANTINEOPLASTIC AGENT; CATECHIN;

ABCG2 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIARY TRACT CANCER; CANCER CELL LINE; CD133 GENE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; P21 GENE; ANALOGS AND DERIVATIVES; APOPTOSIS; BILIARY TRACT TUMOR; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BILIARY TRACT NEOPLASMS; CATECHIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; HUMANS;

EID: 84934924521     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-015-0721-5     Document Type: Article

References (41)

1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215-29. doi 10.1053/j.gastro.2013.10.013
2. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273-81. doi 10.1056/NEJMoa0908721
3. Patel T. Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8(4):189-200. doi 10.1038/nrgastro.2011.20
4. Hu G, Zhang L, Rong Y, Ni X, Sun Y. Downstream carcinogenesis signaling pathways by green tea polyphenols: a translational perspective of chemoprevention and treatment for cancers. Curr Drug Metab. 2014;15(1):14-22.
5. Fujiki H, Sueoka E, Watanabe T, Suganuma M. Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds. J Cancer Res Clin Oncol. 2014. doi: 10.1007/s00432-014-1899-5 .
6. Du GJ, Zhang Z, Wen XD, Yu C, Calway T, Yuan CS, et al. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 2012;4(11):1679-91. doi 10.3390/nu4111679
7. Kim KC, Lee C. Reversal of Cisplatin resistance by epigallocatechin gallate is mediated by downregulation of axl and tyro 3 expression in human lung cancer cells. Korean J Physiol Pharmacol. 2014;18(1):61-6. doi 10.4196/kjpp.2014.18.1.61
8. Hagen RM, Chedea VS, Mintoff CP, Bowler E, Morse HR, Ladomery MR. Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. Int J Oncol. 2013;43(1):194-200. doi 10.3892/ijo.2013.1920
9. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol. 2000;164(1):82-90. doi 10.1006/taap.1999.8885
10. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem Biophys. 2003;410(1):177-85.
11. Lee SH, Nam HJ, Kang HJ, Kwon HW, Lim YC. Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer. 2013;49(15):3210-8. doi 10.1016/j.ejca.2013.06.025
12. Abou El Naga RN, Azab SS. El-Demerdash E, Shaarawy S, El-Merzabani M, Ammar el SM. Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals. Life Sci. 2013;92(10):555-61. doi 10.1016/j.lfs.2013.01.017
13. Takada M, Ku Y, Habara K, Ajiki T, Suzuki Y, Kuroda Y. Inhibitory effect of epigallocatechin-3-gallate on growth and invasion in human biliary tract carcinoma cells. World J Surg. 2002;26(6):683-6. doi 10.1007/s00268-001-0290-2
14. Senggunprai L, Kukongviriyapan V, Prawan A, Kukongviriyapan U. Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK/STAT signaling pathway. Phytother Res. 2014;28(6):841-8. doi 10.1002/ptr.5061
15. Lang M, Henson R, Braconi C, Patel T. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int. 2009;29(5):670-7. doi 10.1111/j.1478-3231.2009.01984.x
16. Kwak TW, Kim Do H, Chung CW, Lee HM, Kim CH, Jeong YI, et al. Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells. Evid Based Complement Alternat Med. 2013;2013:185158. doi: 10.1155/2013/185158 .
17. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer. 1992;52(2):252-60.
18. Oertel M, Schastak SI, Tannapfel A, Hermann R, Sack U, Mossner J, et al. Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model. J Photochem Photobiol B. 2003;71(1-3):1-10.
19. Scherdin G, Garbrecht MMK. In vitro interaction of a-difluoromethylornithine (DFMO) and human recombinant interferon-a (rIFN-a) on human cancer cell lines. Immunobiology. 1987;175:1-143.
20. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol. 1985;1(6):579-96.
21. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995;177(1):61-71.
22. Purdum 3rd PP, Ulissi A, Hylemon PB, Shiffman ML, Moore EW. Cultured human gallbladder epithelia. Methods and partial characterization of a carcinoma-derived model. Lab Invest. 1993;68(3):345-53.
23. Kiesslich T, Alinger B, Wolkersdorfer GW, Ocker M, Neureiter D, Berr F. Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol. 2010;36(1):49-58.
24. Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C, et al. Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci. 2012;8(1):15-29.
25. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368-78. doi 10.1056/NEJM199910283411807
26. Kiesslich T, Neureiter D, Alinger B, Jansky GL, Berlanda J, Mkrtchyan V, et al. Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem Photobiol Sci. 2010;9(5):734-43. doi 10.1039/b9pp00201d
27. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-81. doi 10.1124/pr.58.3.10
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. doi 10.1006/meth.2001.1262
29. Stadnisky MD, Quinn J. Flow Cytometry Analysis Automation and Cloud Integration with FlowJo Version 10. Genetic Eng News. 2012;33(1):38-9.
30. Lecumberri E, Dupertuis YM, Miralbell R, Pichard C. Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr. 2013;32(6):894-903. doi 10.1016/j.clnu.2013.03.008
31. Zhou DH, Wang X, Feng Q. EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells. Nutr Cancer. 2014;66(4):636-44. doi 10.1080/01635581.2014.894101
32. Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO. Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane. J Oncol. 2013;2013:872957. doi: 10.1155/2013/872957 .
33. Singh M, Bhui K, Singh R, Shukla Y. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Sci. 2013;93(1):7-16. doi 10.1016/j.lfs.2013.02.001
34. Yunos NM, Beale P, Yu JQ, Huq F. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells. Anticancer Res. 2011;31(4):1131-40.
35. Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012;31(2):73-99. doi 10.5732/cjc.011.10320
36. Berridge MJ. Cell Cycle and Proliferation. Cell Signalling Biology. 2012. doi: 10.1042/csb0001009
37. Iwahashi S, Utsunomiya T, Shimada M, Saito Y, Morine Y, Imura S, et al. High expression of cancer stem cell markers in cholangiolocellular carcinoma. Surg Today. 2013;43(6):654-60. doi 10.1007/s00595-012-0437-9
38. Leelawat K, Keeratichamroen S, Leelawat S, Tohtong R. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2. Oncol Lett. 2013;6(5):1439-46. doi 10.3892/ol.2013.1587
39. Wang M, Xiao J, Shen M, Yahong Y, Tian R, Zhu F, et al. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer. 2011;128(1):72-81. doi 10.1002/ijc.25317
40. Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T. The role of polycomb repressive complexes in biliary tract cancer. Expert Opin Ther Targets. 2014:1-13. doi: 10.1517/14728222.2014.986460 .
41. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, Eckert RL. (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis. 2011;32(10):1525-32. doi 10.1093/carcin/bgr171